The activities of SOTHEMA have trained the complementarity between license products and clean branded products in the 2024 financial year in a growing market. The private market remains the main engine, which is supported by growth in all therapeutic areas, in particular oncology, which corresponds to 31.5% of annual growth, the company announced in a press release.
In Ledatail, Morocco represents the group’s first market, followed by the countries of the Gulf Cooperation Council (CCG) and French speaking Africa, and is reflected in order to strengthen the presence of SOTHEMA in these areas with great potential.
At the end of December 2024, the consolidated aid of Aires was 2.81 billion ie, an increase of 13.2% compared to 2023. Note that the income from the production and design has increased by 10% and 58% of the CHIO anger from a total of 2024 have been marked. The year 2024 was also marked by the wide portfolio with the start of 18 new products, with 18 new products with the wide portfolio marked with the introduction of 18 new products.
“The balance sheet of 2024 is very satisfactory with growing activities, improvement renovation and in particular concrete performance in all axes that we have considered priority. We have invested in our capacities, expanded our portfolio and intensified our international presence,” says Lamia Tazi, CEO of Sothema.
SOTHEMA also recorded an increase of 23.1% of its EBITDA, which was 600 million DH, which was due to an improvement in the operating margin of 1.5 points, to 19%. This performance results from the favorable development of the product mix, which are geared towards therapeutic areas with higher added value, a good commercial dynamic and the continuation of the production costs of the production costs, the group. The latter thus recorded an RNPG of 315 million DH and grew by 19.8% compared to 2023. The board of directors will propose the distribution of a gross dividend of 28 DH/measures (compared to 17 DH in 2023) for a total amount of 201.6 million.
For this year, the group will further strengthen its therapeutic performance with the introduction of 15 new products, including a large biosimilar in oncology, a generic product for the treatment of multiple sclerosis and a medication based on medical cannabis that is intended for epilepsy. It will launch the production of injectable carpelns in Morocco and the production of anti -cancer within Axis Pharma.
